首页/数据集/Treatment-emergent adverse events during the treatment period (SAS).

Treatment-emergent adverse events during the treatment period (SAS).

Figshare2019-04-03 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Treatment-emergent_adverse_events_during_the_treatment_period_SAS_/7948130 数据链接链接失效反馈

官方服务：

资源简介：

Treatment-emergent adverse events during the treatment period (SAS).

应用场景：

创建时间：

2019-04-03

药物安全性评估

临床试验不良事件

Data are number (%) of patients with at least one adverse event. The safety population consisted of all participants randomly assigned to treatment groups and treated. MedDRA version 14.0 was used for

NIAID Data Ecosystem90

Number (%) of Subjects with Adverse Events During Days 1 to 28.

疫苗安全性监测

临床试验不良事件

Note: *Determined by the investigator to be possibly or probably related to the study vaccine.

NIAID Data Ecosystem50

Safety subgroup analyses in all trials combined.

药物安全性评价

临床亚组分析

Abbreviation: RR: relative risk; BV: bevacizumab.*Cardiac events including: left ventricular (LV) dysfunction and congestive heart failure.**Pulmonary events including: embolism, dyspnea, pneumonitis

Figshare2015-12-03 更新40

Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats

药物安全性评价

消化道微生物组

Proton pump inhibitors (PPIs) are used for the long-term treatment of gastroesophageal disorders and the non-prescription medicines for acid reflux. However, there is growing concerns about PPI misuse

NIAID Data Ecosystem60

Percentage of children with a solicited adverse event during one or more of the treatment rounds.

儿童药物安全性

临床试验不良事件

*p-value from a comparison of the three treatment groups using Fisher's exact test. % refers to the proportion of children who reported an adverse event on any occasion after drug administration.

NIAID Data Ecosystem50

Treatment-emergent adverse events during the treatment period (SAS).

资源简介：

相关数据集